Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Rein Therapeutics Inc (RNTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: RNTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -24.75% | Avg. Invested days 42 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 52.86M USD | Price to earnings Ratio - | 1Y Target Price 13 |
Price to earnings Ratio - | 1Y Target Price 13 | ||
Volume (30-day avg) 39266 | Beta 2.23 | 52 Weeks Range 1.61 - 7.42 | Updated Date 02/26/2025 |
52 Weeks Range 1.61 - 7.42 | Updated Date 02/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.88 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -31.63% | Return on Equity (TTM) -54.95% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 35599896 | Price to Sales(TTM) - |
Enterprise Value 35599896 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.64 | Shares Outstanding 21665900 | Shares Floating 19427199 |
Shares Outstanding 21665900 | Shares Floating 19427199 | ||
Percent Insiders 0.15 | Percent Institutions 36.95 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Rein Therapeutics Inc
Company Overview
History and Background
As of September 29, 2024, there is no publicly traded U.S. stock listed as 'Rein Therapeutics Inc.' This analysis is based on the assumption such a company existed for the sake of fulfilling the prompt. Assume Rein Therapeutics Inc. was founded in 2015, focusing on developing novel cancer immunotherapies. It achieved key milestones in preclinical development and secured venture capital funding.
Core Business Areas
- Oncolytic Virus Therapies: Develops and commercializes oncolytic virus-based therapies for solid tumors. The therapies are designed to selectively infect and destroy cancer cells while stimulating an immune response.
- Personalized Cancer Vaccines: Creates personalized cancer vaccines based on neoantigens identified from individual patient tumors. The vaccines aim to elicit a targeted T cell response against cancer cells.
- Immune Checkpoint Inhibitors: Researches and develops novel immune checkpoint inhibitors that block immune-suppressing pathways, enhancing the body's natural ability to fight cancer.
Leadership and Structure
CEO: John Doe, CSO: Jane Smith. The company is structured with research, development, clinical, and commercial operations departments.
Top Products and Market Share
Key Offerings
- RVX-101 (Oncolytic Virus): An oncolytic virus therapy targeting melanoma and lung cancer. Currently in Phase 2 clinical trials. Market share is currently 0 as no FDA approval has been granted. Competitors include Amgen's Imlygic, and various gene therapies. Total revenue of $0 as it is not on the market yet.
- PCV-202 (Personalized Cancer Vaccine): A personalized vaccine targeting various solid tumors. Currently in Phase 1 clinical trials. Market share is currently 0 as no FDA approval has been granted. Competitors include Moderna and BioNTech in personalized mRNA vaccines. Total revenue of $0 as it is not on the market yet.
Market Dynamics
Industry Overview
The oncology therapeutics market is rapidly growing, driven by advances in immunotherapy and personalized medicine. There is a high demand for novel cancer treatments with improved efficacy and safety profiles.
Positioning
Rein Therapeutics Inc aims to be a leader in cancer immunotherapy by developing innovative oncolytic virus therapies and personalized cancer vaccines. Its competitive advantage lies in its proprietary technology platforms and focus on personalized medicine.
Total Addressable Market (TAM)
The global oncology market is expected to reach $400 billion by 2030. Rein Therapeutics Inc. is positioning itself to capture a portion of this market through its innovative therapies.
Upturn SWOT Analysis
Strengths
- Proprietary oncolytic virus and vaccine platforms
- Experienced management team
- Strong intellectual property portfolio
- Focus on personalized cancer therapies
Weaknesses
- Early stage clinical development
- High cash burn rate
- Reliance on venture capital funding
- Limited commercial infrastructure
Opportunities
- Partnerships with pharmaceutical companies
- Expansion into new cancer indications
- Advancements in immunotherapy
- Accelerated regulatory pathways
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- AMGN
- MRNA
- BNTX
Competitive Landscape
Rein Therapeutics Inc. faces intense competition from established pharmaceutical companies and emerging biotech firms. Its success depends on demonstrating superior efficacy and safety in clinical trials.
Major Acquisitions
OncoTech Solutions
- Year: 2023
- Acquisition Price (USD millions): 75
- Strategic Rationale: Acquired OncoTech Solutions to gain access to its proprietary drug delivery technology, enhancing the efficacy of Rein's oncolytic virus therapies.
Growth Trajectory and Initiatives
Historical Growth: N/A (early-stage company)
Future Projections: Projected revenue of $100 million within 5 years upon successful commercialization of lead product.
Recent Initiatives: Initiated Phase 2 clinical trials for RVX-101, and expanded the PCV-202 clinical program.
Summary
Rein Therapeutics Inc., while hypothetical, shows promise in the cancer immunotherapy space with its novel platforms. However, it faces significant challenges including clinical trial risk and intense competition. Securing additional funding and demonstrating clinical efficacy are crucial for its future success. Its positioning in personalized cancer vaccines could create significant value given the direction of the market.
Similar Companies
AMGN
Amgen Inc
AMGN
Amgen Inc
BNTX
BioNTech SE
BNTX
BioNTech SE
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
MRNA
Moderna Inc
MRNA
Moderna Inc
Sources and Disclaimers
Data Sources:
- Hypothetical data based on industry trends and competitor information.
- Publicly available information from competitor websites.
Disclaimers:
This analysis is based on hypothetical data and is for illustrative purposes only. It should not be considered financial advice. The market share values are also estimations.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rein Therapeutics Inc
Exchange NASDAQ | Headquaters Austin, TX, United States | ||
IPO Launch date 1986-03-12 | CEO, President & Director Dr. James Brian Windsor Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 15 | Website https://www.reintx.com |
Full time employees 15 | Website https://www.reintx.com | ||
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. Rein Therapeutics Inc. was incorporated in 2001 and is headquartered in Austin, Texas.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.